Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (234)	11/1/1997 1:59:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 328

Miljenko, I'm optimistic about the Amphotericin B v. Ambisome battle. I would think that liability concerns by doctors (and perhaps even more important HMO's) will eventually force the widespread adoption of Ambisome. What is a doctor's defense to a patient who suffers renal damage from Ampho B? "I didn't use the equally efective safer drug because it's more expensive?" Any practising doctors care to comment on this? Can anyone think of analagous drugs which are equally effective but where one has fewer potentially serious side-effects? Peter Peter